Unlock this StockReport nowClick to Unlock

Mabion SA Share Price

MAB PLN83.2 0.2  0.2%

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue PLNm
Operating Profit PLNm
Net Profit PLNm
EPS Reported PLN
EPS Normalised PLN
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps PLN
Capex ps PLN
Free Cashflow ps PLN
Dividend ps PLN
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc PLNm
Working Capital PLNm
Net Fixed Assets PLNm
Net Debt PLNm
Book Value PLNm
Average Shares m
Book Value ps PLN -10.9%

FINANCIAL BRIEF: For the three months ended 31 March 2019, Mabion SA revenues was not reported. Net loss increased 4% to PLN15M. Higher net loss reflects R& D Expenses - Other increase from PLN1.5M to PLN3.3M (expense), Labor & Related Expenses in R&D increase from PLN1.2M to PLN2.4M (expense), Foreign Exchange Gain decrease from PLN774K (income) to PLN0K. Basic Earnings per Share excluding Extraordinary Items increased from -PLN1.22 to -PLN1.09. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Mar '19) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: PLN171.2
(+105.81% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (PLN) (PLN) (PLN) (PLN) (PLN) (PLN)
Consensus Estimate
1m Change
3m Change
1 broker Broker Consensus Trend
Broker Recommendations for Mabion SA
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 1 0

Named Brokers and Analysts
Santander Brokerage Poland Lukasz Kosiarski , Ipopema Securities Michal Bugajski ,

Profile Summary

Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

Directors: Maciej Wieczorek (CSU) , Artur Chabowski (CMG) , Jozef Banach (VSU) , Jolanta Baranowska (CAO) , Grzegorz Grabowicz (MGB) , Slawomir Jaros (MGB) , Jaroslaw Walczak (MGB) , David James (IND) , Krzysztof Kaczmarczyk (IND) 42, Robert Konski (IND) 53, Dirk Kreder (IND) , Tadeusz Pietrucha (IND) ,

No. of Employees: 196 No. of Shareholders: n/a

Last Annual December 31st, 2018
Last Interim March 31st, 2019
Incorporated October 29, 2009
Public Since August 10, 2010
Shares in Issue 13,720,772
Free Float 8.28m (60.3%)
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Warsaw Stock Exchange
Eligible for an ISA? a SIPP?

MAB Share Price Performance MAB Share Price Quote
0.2  0.2%
Traded 4:35pm · Minimum 15 min delayed · NMS:

Latest MAB News Announcements (delayed)

Upcoming MAB Events

Recent ↓
Friday 28th June, 2019 (estimate)
Mabion SA Annual Shareholders Meeting
Tuesday 18th June, 2019
Mabion SA Extraordinary Shareholders Meeting
Thursday 28th June, 2018
Mabion SA Annual Shareholders Meeting
Wednesday 18th April, 2018
Mabion SA Extraordinary Shareholders Meeting
Thursday 16th February, 2017
Mabion SA Extraordinary Shareholders Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy MAB

Access MAB Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis